Therapeutics and Clinical Risk Management

SJR Rank #7,822H-index: 79SJR: 0.730Best quartile: Q1Open AccessAPC: US$2,836Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Dove Medical Press Ltd

Country

New Zealand

Type

journal

SJR by Edition

2022202500.20.40.60.8

Subject Categories

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)Q1
  • Safety ResearchQ1
  • Chemical Health and SafetyQ2
  • Medicine (miscellaneous)Q2
  • Pharmacology (medical)Q2

Areas: Chemical Engineering · Medicine · Pharmacology, Toxicology and Pharmaceutics · Social Sciences

Most published research topics

Asthma and respiratory diseasesAnesthesia and Sedative AgentsAnesthesia and Pain ManagementBone health and osteoporosis researchSepsis Diagnosis and TreatmentEnhanced Recovery After SurgeryVenous Thromboembolism Diagnosis and ManagementPharmaceutical Practices and Patient OutcomesBone health and treatmentsAtrial Fibrillation Management and Outcomes

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs070140210280

Documents per Year

2022202504080120160

Detailed Information

ISSN

1176-6336, 1178-203X

SJR Best Quartile

Q1

Region

Pacific Region

Citations per Document (2 years)

2.63

References per Document

37.63

Coverage

2006-2026

Scope

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.

Metrics from SCImago Journal Rank 2025. View on SCImago